Caribou Biosciences, Inc. (CRBU) analyst actions
Rating and price-target actions on CRBU in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CRBU overview →
5 measured CRBU analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out | Press release | +0.00% | -0.54% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Reach Out | Press release | +0.01% | -0.01% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out | Press release | +1.35% | +0.84% | |
| Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 | Press release | -5.99% | -7.19% | |
| Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 | Press release | +0.18% | +1.07% |
Keep exploring
More CRBU: earnings → · SEC filings → · CRBU overview →